Drug Trial Radar · NCT07527910
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
May 22, 2026
Primary completion
Mar 15, 2030
Study completion Mar 15, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein. The goal of this study is to understand the effect of ALN-PNP with or without tirzepatide on reducing liver fat. The study is looking at: * How well ALN-PNP with and without tirzepatide works * What side effects ALN-PNP might cause * How much ALN-PNP is in the blood at different times * How the body and the liver change after having ALN-PNP, which can help researchers understand why ALN-PNP works better in some people than others
Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNPDrug
Administered per the protocol
TirzepatideDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol Placebo matching ALN-PNP
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in liver fatTime frame: From baseline at week 24
- Percent change in liver fatTime frame: From baseline at week 48
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Arizona Liver Health - Tucson
Tucson, Arizona · Recruiting
Southern California Research Center
Coronado, California · Recruiting
California Liver Research Institute
Pasadena, California · Recruiting
Health Awareness - Jupiter
Jupiter, Florida · Recruiting
Evolution Clinical Trials
Miami, Florida · Recruiting
Tandem Clinical Research, Plaza II
Metairie, Louisiana · Recruiting
Geisinger Medical Center
Danville, Pennsylvania · Recruiting
American Research Corporation
Austin, Texas · Recruiting
Advanced Medical Trials
Georgetown, Texas · Recruiting
American Research Corporation at The Texas Liver Institute
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.